8-K/A: Avalo Therapeutics Completes Acquisition of AlmataBio, Files Pro Forma Financials

Avalo Therapeutics has finalized its acquisition of AlmataBio, providing pro forma financial information reflecting the merger and associated PIPE financing.

Summary

• Avalo Therapeutics acquired AlmataBio in a stock-for-stock transaction, with AlmataBio becoming a wholly-owned subsidiary of Avalo.
• The merger involved the issuance of 171,605 shares of Avalo common stock and 2,412 shares of non-voting convertible preferred stock to former AlmataBio stockholders.
• A cash payment of $7.5 million was made to former AlmataBio stockholders upon the closing of a private placement investment.
• Avalo is obligated to pay up to $20 million in development milestones to former AlmataBio stockholders, contingent on the progress of AVTX-009.
• The acquisition was accounted for as an asset acquisition, with the majority of the fair value attributed to in-process research and development (IPR&D).
• Pro forma financial statements include combined results for the year ended December 31, 2023, and the quarter ended March 31, 2024, reflecting the merger and a related PIPE financing.
• The PIPE financing secured up to $185 million in gross proceeds, with an initial $115.6 million upfront investment.
• AlmataBio's audited financials for the period from April 28, 2023 (inception) to December 31, 2023, show a net loss of $659,000 and cash of $1.8 million.
• The pro forma combined net loss for the year ended December 31, 2023, was $32.2 million, and for the quarter ended March 31, 2024, was $122.2 million.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the acquisition and PIPE financing are positive for future development, the significant pro forma losses and the early stage nature of the company temper the overall sentiment.

Positives

• The acquisition of AlmataBio provides Avalo with the anti-IL-1 asset, AVTX-009.
• The PIPE financing provides substantial funding to support the development of AVTX-009 through Phase 2 trials.
• The pro forma financials provide transparency into the combined entity's financial position.
• The merger is expected to enhance Avalo's pipeline and long-term growth potential.

Negatives

• AlmataBio had an accumulated deficit of $0.7 million and a net loss of $659,000 from inception to December 31, 2023.
• The pro forma combined net loss for the year ended December 31, 2023, was $32.2 million.
• The pro forma combined net loss for the quarter ended March 31, 2024, was $122.2 million.
• Avalo incurred significant transaction costs related to the merger and PIPE financing.

Risks

• The company has incurred losses and negative cash flows from operations since inception.
• The company may need to borrow funds or raise additional equity to achieve its longer-term business objectives.
• The company is subject to risks inherent in an early-stage company, including the potential need for additional financing and limited management resources.
• The company's operating results may be materially affected by the ability to find a partner for the assets.
• The company is required to pay up to $70 million based on the achievement of specified development and regulatory milestones to Leap Therapeutics.
• The company is required to pay sales-based milestones aggregating up to $720 million to Leap Therapeutics upon commercialization.

Future Outlook

The company anticipates that it will continue to incur net losses and negative operating cash flows for the foreseeable future. Management believes that the company's current cash, combined with the net proceeds from its common and preferred stock financing, are adequate to meet its needs for at least the next twelve months. Topline results from a planned Phase 2 trial in HS are expected in 2026 and the upfront funding is expected to fund the asset through this data readout and into 2027.

Industry Context

The acquisition of AlmataBio and its anti-IL-1 asset is a strategic move for Avalo to expand its pipeline in the biotechnology sector, particularly in the area of inflammatory diseases. This is a common strategy in the biotech industry where companies acquire assets to bolster their development programs.

Comparison to Industry Standards

• The acquisition of AlmataBio by Avalo is similar to other biotech mergers where a larger company acquires a smaller one for specific assets or technology.
• The pro forma financial results show significant losses, which is not uncommon for early-stage biotech companies focused on research and development.
• The PIPE financing is a standard method for biotech companies to raise capital for clinical trials and development.
• The milestone payments to former AlmataBio stockholders are typical in biotech acquisitions, incentivizing the development of the acquired asset.
• Comparable companies in the biotech space often have similar financial profiles with high R&D expenses and net losses during the development phase.

Stakeholder Impact

• Shareholders of Avalo will see dilution due to the issuance of new shares for the acquisition and PIPE financing.
• Former AlmataBio stockholders received Avalo stock and potential milestone payments.
• Employees of both companies may experience changes due to the merger.
• Customers and suppliers may see changes in the long term as the combined company develops its products.

Next Steps

• Avalo will continue the development of AVTX-009.
• A Phase 2 trial in patients with hidradenitis suppurativa for AVTX-009 is planned.
• Topline results from the Phase 2 trial are expected in 2026.

Key Dates

Keywords

Avalo Therapeutics, AlmataBio, Merger, Acquisition, PIPE Financing, AVTX-009, Biotechnology, Financial Statements, Pro Forma, In-Process Research and Development